Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — Shareholder Meeting (April 2021)
59 slides from Hyphens Pharma International's shareholder meeting presentation, Apr 28, 2021
Slide 1: Annual General Meeting announcement
4/28/2021 REPL::Annual General Meeting::Voluntary REPL::ANNUAL GENERAL MEETING::VOLUNTARY Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Security HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Announcement Details Announcement Title Annual General Meeting Date &Time of Br
Slide 2: Event dates and attachments
4/28/2021 REPL::Annual General Meeting::Voluntary Text particulars are 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888. Event Dates Meeting Date and Time 28/04/2021 14:00:00 Response Deadline Date 25/04/2021 14:00:00 Event Venue(s) Place
Slide 3: Hyphens Pharma International Limited 3rd Annual General Meeting
HYPHENS PHARMA INTERNATIONAL LIMITED 3RD ANNUAL GENERAL MEETING 28 APRIL 2021
Slide 4: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 5: Corporate Presentation
ORPORA PR ATIC Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 6: Our Strategic Focus
OUR STRATEGIC FOCUS ASEAN’s Leading Long-Term Goal Pharmaceuticals & Asia’s No. 1 Consumer Healthcare Skin Health Group Company
Slide 7: Our Business Segments
OUR BUSINESS SEGMENTS 1 Specialty Pharma Principals Ceradan TDF 2 Proprietary Brands CG 210 Ocean Health 3 Medical Hypermart and Digital
Slide 8: Annual Report 2020
ANNUAL REPORT 2020 Deepening Digital Capabilities Expanding Regionally Widening Product Portfolio Creating Value via Intangible Assets Supporting Community Outreach Financial Performance Rewarding Shareholders
Slide 9: Deepening Digitalisation Capabilities
1 DEEPENING DIGITALISATION CAPABILITIES 8:51 Building the Digital Transformation Talent Pool are available in Senior Manager, Digital Transformation E-Commerce & Digital Services Manager Shopee Lazada Qoo10 Amazon Associate E-Commerce Manager
Slide 10: Expanding Regionally
2 EXPANDING REGIONALLY JSPharma Shanghai Good Luck 上海古腊国际 South Korea 贸易有限公司 Mainland China Healthguard SUTL HK Pharmacy Limited Hong Kong, Macau and Duty-Free Sri Lanka Channels in China
Slide 11: Widening Product Portfolio
3 WIDENING PRODUCT PORTFOLIO Hyphens has acquired the rights, titles and interests in the trademarks of CG 210® for Singapore & Malaysia CG 210® is a globally renowned & patented topical botanical hair growth-promoting agent New brand ownership adds to our Proprietary Brands business segment
Slide 12: Widening Product Portfolio
3 WIDENING PRODUCT PORTFOLIO Patent for Ceradan® Advanced technology in UK. Patent pending in 13 other countries/ region. New product launches: + Ceradan® facelift:
Slide 13: Widening Product Portfolio
3 WIDENING PRODUCT PORTFOLIO NEW
Slide 14: Creating Value via Intangible Assets
4 CREATING VALUE VIA INTANGIBLE ASSETS
Slide 15: Supporting Community Outreach
5 SUPPORTING COMMUNITY OUTREACH to give back to our communities
Slide 16: Financial Performance
6.1 FINANCIAL PERFORMANCE Revenue (S$’m) Profit After Tax (S$’m) 6.5 120.9 6.1 6.2 112.7 119.4 123.7 101 5.4 5.2
Slide 17: Revenue by Business Segments
6.2 REVENUE BY BUSINESS SEGMENTS 140.0 120.0 100.0 Revenue S$’mil 57% 55% 52% 80.0 60.0 11% 12% 15% 40.0 20.0 32% 33% 33% 0.0 FY2018 FY2019 FY2020 Specialty 69.4 65.1 64.6 Proprietary 13.2 14.5 18.2 Hypermart 38.3 39.8 40.9 Total 120.9 119.4 123.7
Slide 18: EBITDA by Business Segments
6.3 EBITDA BY BUSINESS SEGMENTS 12.0 9.0 10.1 9.3 10.0 8.0 EBITDA S$’mil 6.2 Specialty 6.0 7.2 6.1 Proprietary 4.0 Hypermart 1.0 Unallocated 2.0 0.9 2.2 3.4 1.9 1.1 0.0 FY2018 FY2019 FY2020 -2.0 EBITDA margin Specialty 10.4% 9.5% 9.4% Proprietary 6.8% 6.9% 12.1% Hypermart 5.0% 8.5% 2.7%
Slide 19: Rewarding Shareholders
7 REWARDING SHAREHOLDERS S$’000 Dividend Yield(a) Div / NP(b) FY2020 0.62 cents 1.9% 30.2% (subj to shareholders’ approval) FY2019 1 cent 3.1% 46.0% FY2018 0.55 cents 1.7% 30.5% (a) Yield is computed based on total dividends declared for the financial year divided by closing price of S$0.32 @ 23 Apr
Slide 20: Business Outlook
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 21: Investing for Growth
INVESTING FOR GROWTH 1. Investment in Proprietary Brands 2. Internationalisation 3. Going Digital 4. Strengthen Specialty Pharma portfolio 5. Acquisitions 6. Challenges – COVID-19
Slide 22: Questions & Answers
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 23: Questions from Shareholders
QUESTIONS FROM SHAREHOLDERS Q1: For the past 3 years, Group revenue is stagnant at around S$120 million and profit net of tax is also stagnant at around S$6 million. Is the Company concerned with this stagnation? Where is the growth going to come from, both top line and bottom line? Q2: Hyphens mark
Slide 24: Questions from Shareholders
QUESTIONS FROM SHAREHOLDERS Q3: Although the China market holds enormous opportunities, it is also very competitive. As such, can the management please share the China expansion/ marketing strategy for Ceradan? Where/How is Ceradan sold in China? Q4: Why did Hyphens only market TDF Fairence in the S
Slide 25: Questions from Shareholders
QUESTIONS FROM SHAREHOLDERS Q6: Why did revenue of Medical Hypermart & Digital segment increase from S$39.8 million to S$40.8 million yet EBITDA declined from S$3.4 million to S$1.1 million? Did you face more competition that necessitated a reduction in your margins? Q7: Hyphens had signed a memoran
Slide 26: Resolutions
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 27: Resolution 1: Adopt Directors' Statement and Audited Financial Statements
RESOLUTION 1 To receive and adopt the Directors’ Statement and Audited Financial Statements of the Company for the financial year ended 31 December 2020 together with the Auditors’ Report thereon. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 241,290,256 100 -
Slide 28: Resolution 2: Final dividend
RESOLUTION 2 To declare a final tax exempt (one-tier) dividend of 0.62 Singapore cents per ordinary share for the financial year ended 31 December 2020. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 241,290,256 100 - - -
Slide 29: Resolution 3
RESOLUTION 3 To re-elect Mr Heng Wee Koon under Regulation 97 of the Constitution. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 234,669,056 97.26 6,621,200 2.74 -
Slide 30: Resolution 4
RESOLUTION 4 To re-elect Mr Ng Eng Leng under Regulation 97 of the Constitution. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 234,669,056 97.26 6,621,200 2.74 -
Slide 31: Resolution 5
RESOLUTION 5 To re-elect Mr Chan Kiat under Regulation 103 of the Constitution. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 241,290,256 100 - - -
Slide 32: Resolution 6: Directors' fees
RESOLUTION 6 To approve the Directors’ fees of SGD 184,900 for the year ended 31 December 2020. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 126,863,895 100 - - 114,426,361
Slide 33: Resolution 7
RESOLUTION 7 To re-appoint RSM Chio Lim LLP as auditors of the Company and to authorise the Directors to fix their remuneration. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 234,669,056 97.26 6,621,200 2.74 -
Slide 34: Resolution 8
RESOLUTION 8 To authorise Directors to allot and issue new shares pursuant to Section 161 of the Companies Act (Chapter 50) and Rule 806 of the SGX-ST Listing Manual Section B: Rule of Catalist. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 234,622,900 97.24 6
Slide 35: Resolution 9
RESOLUTION 9 To authorise Directors to grant awards and issue shares in accordance with Hyphens Performance Share Plan. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 120,127,339 94.75 6,657,356 5.25 114,505,561
Slide 36: Resolution 10
RESOLUTION 10 To authorise Directors to grant options and issue shares in accordance with Hyphens Share Option Scheme. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 120,127,339 94.75 6,657,356 5.25 114,505,561
Slide 37: Scrutineer's Certificate
7] goss SCRUTINEER’S CERTIFICATE = .2#E0S2.SS, em ‘www drewnspier com drewcorp 26 April 2021 To: The Board of Directors Hyphens Pharma Intemational Limited (Issuer) Dear Sirs, ‘As scrutineer appointed for the poll conducted at the Annual General Meeting of the Issuer held by way of electronic means
Slide 38: Hyphens Pharma International Limited
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Slide 39: Results of the Annual General Meeting
1. RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 28 APRIL 2021 2. RE-APPOINTMENT OF DIRECTORS 1. RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 28 APRIL 2021 The Board of Directors of Hyphens Pharma International Limited (the “Company”, and together with its subsidiaries, the “Group”) is pleased to a
Slide 40: Poll results
Resolution Number Total No. of For Against and Details Shares Represented Number of Percentage Number of Percentage by Votes For and Against Shares (%) Shares (%) Ordinary Resolution 2 To declare a final tax 241,290,256 241,290,256 100.00 - - exempt (one-tier) dividend of 0.62 Singapore cents per or
Slide 41: Poll results (continued)
Resolution Number Total No. of For Against and Details Shares Represented Number of Percentage Number of Percentage by Votes For and Against Shares (%) Shares (%) Ordinary Resolution 7 To re-appoint RSM 241,290,256 234,669,056 97.26 6,621,200 2.74 Chio Lim LLP as auditors of the Company and authoris
Slide 42: Abstention from voting
(b) Abstention from Voting Details of parties who have abstained from voting on the resolutions tabled at the AGM are set out below: Resolution Number Name Number of Shares and Details Held Ordinary Resolution 6 To approve the Directors’ fees of Tan Chwee Choon(i) 114,426,361 SGD 184,900 for the fin
Slide 43: Re-appointment of Directors
2. RE-APPOINTMENT OF DIRECTORS – STATEMENT PURSUANT TO RULE 704(7) OF THE CATALIST RULES (a) Mr Heng Wee Koon was re-elected as a Director of the Company, he shall remain as the Lead Independent Director, the Chairman of the Audit Committee, a member of the Nominating Committee and a member of the R
Slide 44: Minutes of 3rd Annual General Meeting
3RD ANNUAL GENERAL MEETING Date : 28 April 2021 Place : Video conferencing Present : Refer to the Attendance List CHAIRMAN Mr Lim See Wah presided at the meeting. QUORUM After ascertaining the presence of a quorum, the Chairman called the meeting to order at 2.00 p.m. INTRODUCTION Chairman welcomed
Slide 45: Resolutions 1 and 2
RESOLVED - RESOLUTION 1 - DIRECTORS’ REPORT AND ACCOUNTS That the audited financial statements and the Reports of the Directors and Auditors for the year ended 31 December 2020 submitted to this Meeting be and are hereby received. Proposer : Chairman Seconder : Fang Lee Wei The motion was put to vot
Slide 46: Resolutions 4 and 5
No. Percentage (%) No. of votes in favour of the Resolution 234,669,056 97.26 No. of votes against the Resolution 6,621,200 2.74 No. of votes abstained from voting on the Resolution - - The Chairman declared the motion carried. RESOLVED - RESOLUTION 4 – RE-ELECTION OF DIRECTOR That Mr Ng Eng Leng be
Slide 47: Resolutions 6 and 7
RESOLVED - RESOLUTION 6 – DIRECTORS’ FEES That the Directors’ fees of SGD 184,900 for the year ended 31 December 2020 be hereby approved. Proposer : Chairman Seconder : Fang Lee Wei The motion was put to vote by poll and the results were as follows:- No. Percentage (%) No. of votes in favour of the
Slide 48: Share issue authority resolutions
(i) the aggregate number of shares and/or convertible securities to be issued pursuant to this resolution must not be more than one hundred per cent (100%) of the total number of issued shares excluding treasury shares and subsidiary holdings of the Company (as calculated in accordance with sub-para
Slide 49: Share Option Scheme resolution
(ii) and issue from time to time such number of fully paid-up shares in the capital of the Company as may be required to be allotted and issued pursuant to the vesting of awards under the Performance Share Plan, provided always that the aggregate number of Shares issued and/or issuable pursuant to t
Slide 50: Termination of Meeting
TERMINATION OF MEETING There being no other business, the Meeting ended at 2.25 p.m. with a vote of thanks to the Chair. CONFIRMED AS A TRUE RECORD OF MINUTES _______________________________________ LIM SEE WAH Chairman This document has been prepared by the Company and its contents have been review
Slide 51: Attendance Lists
ATTENDANCE LISTS Physical attendance Name Position Lim See Wah Executive Chairman and CEO Heng Wee Koon Lead Independent Director Lim Sher Mei (Lin Shimei) Company Secretary Fang Lee Wei Chief Financial Officer Attendance via web conference Board of Directors Name Position Tan Chwee Choon Executive
Slide 52: Appendix A: Company's Responses
Appendix A Question 1 Why did revenue of Medical Hypermart & Digital segment increase from S$39.8 million to S$40.8 million yet EBITDA declined from S$3.4 million to S$1.1 million? Did you face more competition that necessitated a reduction in your margins? Company’s Response The lower EBITDA in FY2
Slide 53: Company's Responses
Question 5 Hyphens had signed a memorandum of understanding with Doctor Anywhere, and was awarded e- pharmacy license for WellAway Pharmacy. Other than telemedicine and perhaps onboarding more products / end customers in the B2B platform, are there any other major potential avenues for business grow
Slide 54: Company's Responses
Question 9 As Hyphens deepens its digital transformation, can the management consider sharing its digital initiatives (and outcomes) especially for the proprietary brands in future annual reports, e.g. outline the increase in the number of social media followers / engagements, number of social media
Slide 55: Company's Responses
Question 13 Hyphens markets & sells a range of specialty pharmaceutical products in selected ASEAN countries, and has strong regulatory capabilities as well as significant experience in certain therapeutic areas/ medical specialties. As such, (a) Is Hyphens actively seeking to leverage this strong c
Slide 56: Company's Responses
Question 16 Is the full range of Ocean Health products Halal-Certified? Company’s Response Not the full range but our flagship product, Omega-3 Fish Oil, is Halal-Certified. Question 17 While browsing Ceradan products in Guardian retail stores, I noticed different products have various country label
Slide 57: Company's Responses
Question 20 Hyphens has launched the Ceradan / TDF websites - are there plans to enable ecommerce (online purchase) function on those sites like for Ocean Health? If not, are there any particular reasons? Company’s Response Ceradan is readily available on e-commerce platforms like Shopee, Lazada, Qo
Slide 58: Company's Responses
Question 24 Although the China market holds enormous opportunities, it is also very competitive. As such, can the management please share the China expansion /marketing strategy for Ceradan: (a) Offline: Is Hyphens only marketing Ceradan through medical channels in China (via Shanghai Good Luck)? Wh
Slide 59: Company's Responses
Question 27 Is there a specific overseas expansion playbook Hyphens follow before embarking unto a new market (country): (a) How does Hyphens gauge the potential demand of its proprietary products in a new market? Does Hyphens engage a 3rd party external consultant for such purposes? (b) How does Hy
Hyphens Pharma International — Shareholder Meeting (April 2021) on 6ix